螨变应原特异性免疫治疗疗效相关生物标志物研究进展

Advances in biomarkers of mite allergen specific immunotherapy efficacy

变应原特异性免疫治疗(allergen specific immunotherapy,AIT)是目前公认的针对过敏性疾病病因的治疗方法。随着变应原剂量逐步增加,AIT可诱导机体建立免疫耐受,预防过敏症状加重,减少患者急救用药,阻断过敏性疾病的发展进程,其有效性及安全性得到国内外学者的肯定。成功的AIT可抑制早期及晚期的过敏反应,但是并不是所有患者都对AIT有应答,其总有效率50%~80%不等,且AIT治疗疗程长、费用高。因此,明确可以预测和评价疗效的生物标志物尤为重要。该文对免疫球蛋白、细胞因子的变化与AIT疗效相关性的研究进展作一综述,以期为临床医生提供参考。

Allergen specific immunotherapy(AIT)is currently the only recognized treatment for the cause of allergic diseases.With the gradual increase in the dose of allergens,AIT can induce the body to establish immune tolerance,prevent the aggravation of allergic symptoms,reduce patients'emergency medication,and block the development of allergic diseases.AIT effectiveness and safety have been affirmed by scholars at home and abroad.Successful AIT can inhibit early and late anaphylaxis,but not all patients respond to AIT.The overall response rate ranges from 50%to 80%,and the course of treatment is long and the cost is high.Therefore,it is particularly important to identify biomarkers that can predict and evaluate the efficacy.This article mainly reviews the research progress on the correlation between the changes of biomarkers(immunoglobulin and cytokines)and the efficacy of AIT,in order to provide reference for pediatricians.